Publications

ARTICLE  |  IMMUNOHORIZONS  |  Published: Sept. 17, 2025

Lipid A mimetic BECC438 potentiates durable and balanced antibody responses in an ovalbumin murine model of vaccination

ARTICLE  |  MDPI VACCINES  |  Published: Aug. 14, 2025

Polyphosphazene-Mediated Assembly of TLR4 and TLR7/8 Agonists Enables a Potent Nano-Adjuvant Delivery System for Hepatitis C Virus Vaccine Antigens

ARTICLE  |  VACCINE  |  Published: Feb, 2025

BECC-engineered live-attenuated Shigella vaccine candidates display reduced endotoxicity with robust immunogenicity in mice

ARTICLE  |  VACCINE  |  Published: Dec. 3, 2024

Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice

ARTICLE  |  MDPI VACCINES  |  Published: June 1, 2024

Vaccination with a Protective Ipa Protein-Containing Nanoemulsion Differentially Alters the Transcriptomic Profiles of Young and Elderly Mice following Shigella Infection

ARTICLE  |  ASM Journals  |  Published: Feb. 7, 2024

BECC438b TLR4 agonist supports unique immune response profiles from nasal and muscular DTaP pertussis vaccines in murine challenge models

ARTICLE  |  HELIYON  |  Published: July, 2023

Physicochemical characterization of biological and synthetic forms of two lipid A-based TLR4 agonists

ARTICLE  |  FRONTIERS  |  Published: June 29, 2023

Immunogenicity and protective efficacy of nanoparticle formulations of L-SseB against Salmonella infection

ARTICLE  |  NATURE SCIENTIFIC REPORTS  |  Published: Jan. 2023

Enhancing the protection of influenza virus vaccines with BECC TLR4 adjuvant in aged mice

ARTICLE  |  ASM JOURNALS  |  Published: May 9, 2017

Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery

ARTICLE  |  NPJ VACCINES  |  Published: March 14, 2022

Intranasal administration of BReC-CoV-2 COVID-19 vaccine protects K18-hACE2 mice against lethal SARS-CoV-2 challenge

ARTICLE  |  FRONTIERS  |  Published: Aug. 17, 2021

Effect of Two Unique Nanoparticle Formulations on the Efficacy of a Broadly Protective Vaccine Against Pseudomonas Aeruginosa

ARTICLE  |  VACCINE  |  Published: Aug. 3, 2021

Novel TLR4 adjuvant elicits protection against homologousand heterologous Influenza A infection

ARTICLE  |  VACCINE  |  Published: Aug. 3, 2021

BECC Adjuvanted Vaccine Provides Cross-Protection from Both Homologous and Heterologous Influenza A Infections

ARTICLE  |  VACCINE  |  Published: Dec. 10, 2020

Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists

ARTICLE  |  VACCINE  |  Published: May 31, 2018

A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model

REVIEW  |  F1000 RESEARCH  |  Published: Aug. 7, 2017

Bacterial lipids: powerful modifiers of the innate immune response